immunoglobulin G (Bivigam, Gammagard, Gammagard ERC) — 2026 Medicare Part D coverage
immunoglobulin G — sold as Bivigam, Gammagard, Gammagard ERC, Gammaked, Gammaplex, Gamunex, Octagam, Panzyga, Privigen, Qivigy, Yimmugo: 28 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover immunoglobulin G?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| gamunex-C 10 % in 10 mL Injection brand · RxCUI 1809580 | 295 (90%) | 5 | 293 | 0 | 0 |
| GAMMAGARD 10 % in 25 ML Injection brand · RxCUI 1809667 | 186 (57%) | 5 | 184 | 0 | 0 |
| GAMMAGARD 10 % in 100 ML Injection brand · RxCUI 1809670 | 170 (52%) | 5 | 170 | 0 | 0 |
| GAMMAGARD 10 % in 50 ML Injection brand · RxCUI 1809668 | 170 (52%) | 5 | 170 | 0 | 0 |
| GAMMAGARD ERC 10 % in 100 ML Injection brand · RxCUI 2733847 | 169 (52%) | 5 | 167 | 0 | 0 |
| GAMMAGARD ERC 10 % in 50 ML Injection brand · RxCUI 2733845 | 169 (52%) | 5 | 167 | 0 | 0 |
| privigen 10 % in 200 ML Injection brand · RxCUI 1809520 | 164 (50%) | 5 | 164 | 0 | 0 |
| GAMMAGARD 10 GM Injection brand · RxCUI 1809738 | 150 (46%) | 5 | 148 | 0 | 0 |
| GAMMAGARD 5 GM Injection brand · RxCUI 1809730 | 150 (46%) | 5 | 148 | 0 | 0 |
| octagam 10 % in 20 ML Injection brand · RxCUI 1809499 | 124 (38%) | 5 | 124 | 0 | 0 |
| octagam 5 % in 20 ML Injection brand · RxCUI 1809643 | 121 (37%) | 5 | 119 | 0 | 0 |
| Gammaplex 10 % in 50 ML Injection brand · RxCUI 1876671 | 111 (34%) | 5 | 111 | 0 | 0 |
| Gammaplex 10 % in 200 ML Injection brand · RxCUI 1876674 | 110 (34%) | 5 | 110 | 0 | 0 |
| Gammaplex 10 % in 100 ML Injection brand · RxCUI 1876673 | 109 (33%) | 5 | 109 | 0 | 0 |
| Gammaplex 5 % in 200 ML Injection brand · RxCUI 1809513 | 106 (32%) | 5 | 104 | 0 | 0 |
| gammaked 10 % in 10 ML Injection brand · RxCUI 1809436 | 101 (31%) | 5 | 99 | 0 | 0 |
| Bivigam 10 % in 50 ML Injection brand · RxCUI 1809416 | 95 (29%) | 5 | 95 | 0 | 0 |
| panzyga 10 % in 10 ML Injection brand · RxCUI 2102440 | 67 (20%) | 5 | 67 | 0 | 0 |
| panzyga 10 % in 100 ML Injection brand · RxCUI 2102464 | 66 (20%) | 5 | 66 | 0 | 0 |
| panzyga 10 % in 200 ML Injection brand · RxCUI 2102470 | 66 (20%) | 5 | 66 | 0 | 0 |
| panzyga 10 % in 25 ML Injection brand · RxCUI 2102456 | 66 (20%) | 5 | 66 | 0 | 0 |
| panzyga 10 % in 300 ML Injection brand · RxCUI 2102472 | 66 (20%) | 5 | 66 | 0 | 0 |
| panzyga 10 % in 50 ML Injection brand · RxCUI 2102460 | 66 (20%) | 5 | 66 | 0 | 0 |
| QIVIGY 10 % in 50 ML Injection brand · RxCUI 2726023 | 6 (2%) | 5 | 6 | 0 | 0 |
| Qivigy 10 % in 100 ML Injection brand · RxCUI 2726026 | 6 (2%) | 5 | 6 | 0 | 0 |
| Yimmugo 10 % in 100 ML Injection brand · RxCUI 2706396 | 1 (0%) | 2 | 1 | 0 | 0 |
| Yimmugo 10 % in 200 ML Injection brand · RxCUI 2706398 | 1 (0%) | 2 | 1 | 0 | 0 |
| Yimmugo 10 % in 50 ML Injection brand · RxCUI 2706393 | 1 (0%) | 2 | 1 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.